Discovery and clinical introduction of first-in-class imipridone ONC201
暂无分享,去创建一个
Neel S. Madhukar | Michael L. Wang | O. Elemento | K. Flaherty | C. Benes | M. Andreeff | W. El-Deiry | D. Dicker | J. Bertino | G. Borthakur | Amriti R Lulla | Avital Lev | Lanlan Zhou | Gen Sheng Wu | F. Al-Mulla | C. L. Kline | B. Lim | W. Oster | H. Kaufman | M. Duvic | M. Stein | L. Schalop | R. Pottorf | Jessica Wagner | Joshua E. Allen | V. Prabhu | M. Stogniew | J. Ishizawa | M. Talekar | Marie Baumeister | B. R. Nallaganchu | G. Olson | J. Allen | M. Baumeister | J. Allen | Mala K. Talekar
[1] Hong Wang,et al. The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent. , 2016, Biochemical and biophysical research communications.
[2] S. Lipkowitz,et al. ONC201: Stressing tumors to death , 2016, Science Signaling.
[3] Michael L. Wang,et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies , 2016, Science Signaling.
[4] W. El-Deiry,et al. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases , 2016, Science Signaling.
[5] M. Duvic,et al. ONC201 Induces Apoptosis in Cutaneous T-Cell Lymphoma Cells through a Mechanism That Involves the Integrated Stress Response and Inactivation of Jak/Stat Signaling , 2015 .
[6] W. El-Deiry,et al. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent , 2015, PloS one.
[7] P. Canoll,et al. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo , 2015, Oncotarget.
[8] W. El-Deiry,et al. Abstract 2942: TRAIL pathway inducer ONC201/TIC10 primes multiple myeloma cells (MM) for apoptosis by downregulating X-linked inhibitor of apoptosis , 2015 .
[9] W. El-Deiry,et al. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells , 2015, Cell cycle.
[10] R. DiPaola,et al. First-in-human dose escalation study of oral ONC201 in advanced solid tumors. , 2015 .
[11] G. Ouyang,et al. Cancer stem cells: a potential target for cancer therapy , 2015, Cellular and Molecular Life Sciences.
[12] W. El-Deiry,et al. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway , 2015, Molecular Cancer.
[13] Wafik S El-Deiry,et al. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. , 2015, Cancer research.
[14] W. El-Deiry,et al. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. , 2015, Cancer research.
[15] D. Dicker,et al. Genetic andPharmacological ScreensConverge in Identifying FLIP , BCL 2 , and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC 201 / TIC 10 , 2015 .
[16] M. Andreeff,et al. ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples , 2014 .
[17] W. El-Deiry,et al. Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins , 2014 .
[18] W. El-Deiry,et al. The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity , 2014, Oncotarget.
[19] D. Sasseville,et al. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression , 2014, Cell cycle.
[20] W. Cavenee,et al. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma , 2014, Oncotarget.
[21] V. Carraro,et al. The eIF2α/ATF4 pathway is essential for stress-induced autophagy gene expression , 2013, Nucleic acids research.
[22] R. Kaufman,et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death , 2013, Nature Cell Biology.
[23] E. Messaris,et al. Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects , 2013, Science Translational Medicine.
[24] S. Salhi,et al. Translation termination efficiency modulates ATF4 response by regulating ATF4 mRNA translation at 5′ short ORFs , 2012, Nucleic acids research.
[25] B. Leber,et al. Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells , 2012, Cell.
[26] C. Wirtz,et al. Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis , 2011, Clinical Cancer Research.
[27] Hans Clevers,et al. The cancer stem cell: premises, promises and challenges , 2011, Nature Medicine.
[28] R. Tiwary,et al. Role of Endoplasmic Reticulum Stress in α-TEA Mediated TRAIL/DR5 Death Receptor Dependent Apoptosis , 2010, PloS one.
[29] J. Olson,et al. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma , 2010, Journal of Neuro-Oncology.
[30] M. Maggiolini,et al. G protein-coupled receptors: novel targets for drug discovery in cancer , 2010, Nature Reviews Drug Discovery.
[31] Christina Falschlehner,et al. Following TRAIL’s path in the immune system , 2009, Immunology.
[32] F. Khuri,et al. Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. , 2008, Cancer research.
[33] G. Mills,et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation , 2008, Nature Cell Biology.
[34] S. Pileri,et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Chanan-Khan,et al. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. , 2007, The oncologist.
[36] J. Monbaliu,et al. Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib , 2007, Cancer Chemotherapy and Pharmacology.
[37] J. Monbaliu,et al. Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib. , 2007, Cancer chemotherapy and pharmacology.
[38] M. Dyer,et al. Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin’s lymphoma , 2006, Proceedings of the National Academy of Sciences.
[39] T. Shiraishi,et al. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. , 2005, Cancer research.
[40] H. Hayashi,et al. TRB3, a novel ER stress‐inducible gene, is induced via ATF4–CHOP pathway and is involved in cell death , 2005, The EMBO journal.
[41] Michael L. Wang,et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Michael Q. Zhang,et al. From worm to human: bioinformatics approaches to identify FOXO target genes , 2005, Mechanisms of Ageing and Development.
[43] R. Millikan,et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] J. Xu,et al. Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects. , 2004, World journal of gastroenterology.
[45] Marc Montminy,et al. TRB3: A tribbles Homolog That Inhibits Akt/PKB Activation by Insulin in Liver , 2003, Science.
[46] J. Gu,et al. Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene. , 2003, International journal of oncology.
[47] Rakesh Nagarajan,et al. FOXO Proteins Regulate Tumor Necrosis Factor-related Apoptosis Inducing Ligand Expression , 2002, The Journal of Biological Chemistry.
[48] S. Curley,et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. , 2001, Cancer research.